Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (DUET-1)

NCT03411915 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT03411915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03411915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (DUET-1)
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 22, 2018
Completion date
October 26, 2021
Enrollment
62 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neoplasm, neuroendocrine tumor